SUMMARY
With improvement in surgical techniques and particularly the development of immunosuppressant drugs like cyclosporine, liver transplantation has become the first choice treatment for patients suffering end-stage liver disease. Orthotopic liver transplantation currently has one-year survival rates exceeding 80% 1 . Allograft failure remains an important cause of morbidity and mortality and leads to retransplantation in 10 to 20% of patients 2 . The major causes of graft failure are acute rejection, technical failure and primary dysfunction (PDF). PDF is related to preservation injury and represents a range of injuries from initial poor function to primary nonfunction (PNF). PNF is the most severe form of posttransplant primary dysfunction and is known to lead to the development of multiple organ failure. PNF is irreversible and retransplantation is the only treatment. Thus, a rapid and reliable early quantitative assessment of hepatic function following transplantation is of importance because it may allow prompt detection of graft failure due to technical failure or PDF. Early diagnosis may allow surgical correction of technical problems, or immediate placement on a list for retransplantation.
Although there are numerous liver function tests, most of the commonly used tests, such as serum aminotransferase and alkaline phosphatase tests, are not true organ function tests. They reflect primarily the presence or absence of hepatobiliary damage rather than the activity of the functioning liver cells. There have been many studies to identify an appropriate liver function test to assess graft function, and numerous publications have reported evidence of altered drug disposition in patients with liver diseases 3 . Thus administering an indicator or drug and measuring its clearance may prove useful for assessing liver function immediately following surgery.
To assess liver function by examining drug disposition the ideal agent would have to display the following characteristics: 1. It would be nontoxic and lack pharmacological effects. 2. It would preferably be given intravenously. If given orally it would be completely and rapidly absorbed.
3. The rate-determining steps of elimination would be affected by hepatic disease but not by other pathophysiologic conditions or drugs. 4. It would be eliminated primarily by the hepatic route. 5. The parent compound, its metabolite(s) or both should be measurable in plasma, or the appropriate biological fluid including saliva, urine or breath. 6. It would not be extensively protein-bound in blood or tissues unless it had a high extraction ratio. 7. It would be inexpensive. 8 . Reliable assays of the agent and/or metabolite(s) would be readily available. 9. The agent would be generally available for human use. Recent published studies have used several agents to characterize liver function (Table 1) . Their use is summarized as follows:
Lignocaine
Lignocaine is metabolized to mono-ethyleneglycinexylidide (MEGX) via oxidative N-de-ethylation by the hepatic cytochrome P450 enzyme system. The rate of MEGX formation reflects the clearance of lignocaine 4 . Measurement of MEGX concentrations as a quantitative test of liver function has been used to reflect the severity of functional liver damage in cirrhotic patients as well as in predicting graft survival after liver transplantation 4, 5 . The relationship between MEGX formation and severity of hepatic dysfunction in adult patients with chronic liver disease has been evaluated 6 . Lignocaine (1 mg/kg) was injected intravenously over one minute, and a single venous blood sample was taken 15 minutes later. Serum MEGX concentration was measured using a fluorescence polarization immunoassay with a TDx ® analyser. The results indicated that serum MEGX concentration was inversely proportional to the severity of hepatic dysfunction as represented by Pugh's score (P<0.05). Taking a MEGX concentration below 54 ng/ml (262 nM) as an indicator of hepatic dysfunction, the diagnostic sensitivity was 85%, the specificity 89% and the accuracy 86%. In surgical intensive care patients, MEGX formation, as an indicator of liver dysfunction, has been compared with other liver function parameters including: serum concentrations of aspartate aminotransferase, alanine aminotransferase, alkaline phosphatase, cholinesterase, antithrombin 3, bilirubin, creatinine and prothrombin time 7 . Significant differences in MEGX values were found between survivors and non-survivors (P<0.01). Bilirubin was the only other measurement that showed a significant difference (P<0.05) when the non-survivor group was compared with the survivor group. These authors concluded that assessment of MEGX formation was an easy, rapid and specific technique to evaluate liver function. These positive conclusions were not supported by a study of 111 patients with well characterized liver disease 8 , which showed that MEGX values varied over a very wide range, even among patients with similar disease aetiology, activity and impairment of liver function. The MEGX test did not seem to discriminate patients with minimal liver disease from those with more advanced liver disease as well as the Aminopyrine Breath Test or Galactose Elimination Capacity Test. The MEGX test in liver donors also failed to predict post-graft liver function 9, 10 in the recipient. The results of the MEGX test will be affected by changes in liver blood flow (common in recipients of liver transplants) because lignocaine has a high first-pass hepatic extraction, and by administration of drugs that interfere with the CYP450 enzyme system. MEGX tests in recipients two days post-operation do show a good correlation with liver function 9 . Another study used the MEGX test at 12, 24, 48 and 72 hours after graft revascularization to assess transplant liver function in 71 patients 11 . The MEGX test was a sensitive method reflecting early graft liver function. In all cases in which MEGX values were above 60 ng/ml (291 nM) 24 hours after unclamping, the initial recovery was uncomplicated. One year survival was nearly 100%, even if some conventional liver function tests were altered. Low MEGX formation must be considered together with conventional liver function tests. Only in combination with an altered biochemical test does it reflect a graft injury. However, a persistent MEGX formation below 20 ng/ml (97 nM) was prognostic of need for retransplantation. Therefore, the authors proposed a combination of the MEGX test with a conventional liver function test in assessing graft liver function in clinical practice.
The single blood sample required for the MEGX test is an advantage over the serial samples required for other quantitative liver function tests, such as Galactose Elimination Capacity, Indocyanine Green (ICG) clearance and Caffeine clearance test. Moreover, the results can be obtained within 20 minutes by employing the fluorescence polarization immunoassay which is rapid and easy to perform (note: bilirubin level >12 mg/dl can interfere with this assay). The disadvantage of the MEGX test is that drugs like phenobarbital, rifampicin or cimetidine that interfere with the activity of the hepatic CYP450 enzyme system may affect MEGX formation. Allergy to lignocaine is rare and significant direct cardiovascular effects are unlikely at the low dose used for the MEGX test.
Indocyanine Green
The use of indocyanine green (ICG), a watersoluble tricarbocyanine dye, to measure blood flow and identify cardiac abnormalities, was described in 1957 12 . After intravenous injection, ICG is completely bound to plasma proteins with 95% being bound to albumin. ICG is rapidly and exclusively extracted by hepatocytes and excreted almost entirely into bile in an unchanged form 13 . Accordingly, measurement of ICG clearance has been used as a measure of liver function and liver blood flow. In healthy individuals the elimination rate of ICG correlates with liver blood flow. In patients with liver disease, ICG clearance may be decreased due to either reduced liver blood flow or decreased hepatocellular function 14 . To assess hepatocellular function with ICG, it is crucial to account for changes in liver blood flow.
ICG clearance has been used to assess liver function after transplantation. In one study 15 ICG clearance was measured 18 to 24 hours after liver transplantation in 23 patients. Doppler ultrasonography confirmed normal hepatic arterial blood flow in all these patients. A significant correlation was noted between ICG elimination rate and graft liver function 18 to 24 hours after liver transplantation. All patients with ICG clearances of >200 ml/min developed good liver function, whereas all those with clearances of <200 ml/min either died or required retransplantation, or prolonged intensive care. In another study 16 , the ICG elimination test was performed 1, 3 and 7 days postoperatively in 50 orthotopic liver transplant patients. The ICG clearance on day 1 was a better predictor of liver function than any of the conventional liver function tests, and showed significant inverse correlations with the severity of preservation injury, longer intensive care stay, prolonged liver dysfunction and septic complications.
The measurement of ICG clearance usually involves a bolus intravenous injection of ICG, 0.5 mg/kg. Blood samples (2 ml) are then obtained at five-minute intervals for 15 to 30 minutes. ICG absorbance is then measured using a spectrophotometer at a wavelength of either 805 nm or 900 nm. This absorbance value is then converted to an ICG concentration (mg/l) using a standard (calibration) curve. The concentration is then plotted semilogarithmically against time and the least squares line of best fit estimated 17 . The ICG clearance test is a safe and easy method to use; at present it costs approximately $US300 per test and it takes an hour to complete 15 . While the ICG test has not been accepted for routine use clinically, results so far encourage further investigations into the value of this test in assessing liver function in both liver disease patients and liver transplant recipients.
Caffeine
Caffeine is a suitable drug for quantifying liver function since it is rapidly and completely absorbed after oral administration and is then metabolized by hepatic cytochrome P450 enzymes. It is exclusively metabolized in the liver and its degradation products are excreted in urine with less than 3% being excreted unchanged 18 . Caffeine is metabolized mainly via demethylation by the hepatic microsomal enzyme system. Cytochrome P450 IA2 is the main enzyme involved and all the metabolites have a high renal clearance. Impaired elimination of caffeine has been demonstrated in cirrhotic patients 19 . Therefore, it is reasonable to quantify liver function by measuring caffeine clearance in patients suffering from chronic parenchymal liver disease. Caffeine elimination may be determined by measuring caffeine plasma half-life (t 1/2 ) or clearance after an oral or intravenous dose 20 . Another technique to estimate caffeine clearance is the caffeine breath test which measures 14 CO 2 exhalation following an intravenous injection of 14 C-labelled caffeine 21 . Alternatively liver function may be assessed by measuring overnight salivary caffeine concentration which approximates to 75% of the plasma concentration, thus caffeine salivary clearance correlates well with its plasma clearance 22 . Assay of caffeine in plasma or saliva can be accomplished by enzyme-mediated immunoassay (EMIT) or HPLC 20, 22 . Since the correlation between caffeine clearance and liver function was first confirmed in 1980 19 , the caffeine clearance test has been used clinically as a promising quantitative liver function test.
Caffeine clearance has mainly been used to estimate the extent of liver damage in patients with chronic disease. Two studies 20, 22 observed a significant difference in caffeine clearance between patients with severe liver disease and control subjects. It has been recommended as a routine procedure in the assessment of liver function in patients with liver cirrhosis 22 . One limitation of this test is that smoking induces cytochrome P450 1A2 enzyme 23 and may lead to a falsely elevated caffeine clearance. Another problem is that some drugs such as anticonvulsants (generally enzyme inducers) and allopurinol (an inhibitor) may alter caffeine metabolism 24 . So far only one study has used the caffeine clearance test as a quantitative measure of liver function following orthotopic liver transplantation. The caffeine clearance test showed little benefit in the differential diagnosis of early postoperative complications 25 .
Galactose Elimination Capacity (GEC)
Measurement of GEC is another quantitative liver function test which has been used both in research and clinical practice. Galactose is a naturally occurring sugar with a high extraction ratio and is 90% metabolized in the liver 26 . Galactose metabolism is catalysed by galactokinase through epimerization with subsequent conversion to glucose-1-phosphate. The galactokinase reaction is the rate-limiting step in galactose hepatic metabolism 27 . The theory is that the maximal hepatic galactose elimination rate (Vmax) correlates with the total capacity of the liver to phosphorylate galactose which reflects the total amount of functioning liver 28 . The measurement procedure begins with a three-minute intravenous injection of galactose of 0.5 g/kg. Blood samples are then obtained at five-minute intervals from 20 to 45 minutes and urine is also collected. Plasma and urine galactose concentrations are determined enzymatically 29 . GEC is calculated according to the formula 30 :
Q=I-U/T c=0 +7 mmol/min where Q=elimination rate, I=injected galactose dose, U=galactose amount excreted in the urine, T c=0 =time for the concentration to reach zero, extrapolated from a linear regression of the plasma concentration-time data from 25 min after injection, 7=empirical correction for uneven galactose distribution. GEC has been used as a prognostic index in 25 patients with fulminant liver failure 29 . GEC correlated well with routine liver function tests and clinical features. The GEC was the only liver function test significantly higher in the five patients who survived than in the 20 patients who died. All patients with a GEC below 12.8 µmol/min died 29 . In another study, GEC had a better prognostic value than the ABT and ICG clearance tests 31 , and added some new prognostic information to that obtained from the Pugh score.
While GEC provides a valuable index of the severity of liver disease, it seems less valuable for diagnostic purposes in liver transplantation. This might be due to the methodological difficulties in the determination of GEC and other pathophysiological conditions in patients with liver disease 32 . Only limited information is available so far on the use of GEC as a quantitative liver function test for liver transplantation patients and the results are not encouraging. In one study 25 , GEC was measured in 10 orthotopic liver transplant patients during the first 12 days after transplantation. The GEC test showed little benefit in diagnosing complications or predicting the eventual outcome. This might be due to the small number of patients in the study or because of the interaction between various drugs administered postoperatively. In another study 33 , GEC was compared with ICG and MEGX tests for assessment of liver function in the early postoperative period after liver transplantation. The GEC test was abandoned by the authors in the middle of the study because of limited reliability and its cumbersome nature.
Recently, a simple liver function test that measures the 60 minute galactose blood concentration after a rapid intravenous administration of galactose, as a representative measure of residual liver function, has been developed 34 . Unlike the conventional GEC test, which requires serial blood sampling and urine collection, this method requires only one blood sample. In patients with liver cirrhosis, it was well correlated with the severity of the disease 35 and suggested as an alternative to the conventional GEC test 30 . This conclusion was questioned in another study which showed a considerable error associated with the application of the new technique in patients with more advanced liver disease 36 . One limitation of GEC as a liver function test is that extrahepatic pathways for elimination of galactose exist and may account for metabolism of a considerable portion of the administered dose 32 . Despite an empirical correction for urinary excretion, the remaining extrahepatic elimination cannot be determined, which may influence the sensitivity of this test. In addition, GEC is technically more complex compared with other quantitative liver function tests, such as the MEGX formation test, the ICG clearance test or the aminopyrine breath test.
Antipyrine Test
The antipyrine test was introduced over 30 years ago to quantify the effects of individual environmental factors on hepatic drug-metabolizing capacity in healthy subjects 37 . Antipyrine is uniquely suited as a test compound because of its special pharmacokinetic properties that include a rapid and com-plete absorption from the gastrointestinal tract, distribution in total body water with negligible binding to plasma or tissue proteins, almost complete hepatic metabolism with a low hepatic extraction ratio, and negligible renal excretion 38 . The drug was initially used in humans for the determination of total body water because it was found to distribute in total body water 39 . It was not until 1986 that antipyrine was first used in humans to quantify effects of enzyme inducers, such as phenobarbital, on hepatic drug metabolizing capacity 40 . Since then, antipyrine has been used widely in clinical pharmacology to quantify effects of various factors such as environmental pertubations, drugs and diseases on hepatic drug metabolizing capacity 38 . The dispositions of antipyrine and its major metabolites are altered in the presence of several types of liver disease 41, 42 . A consistently lower antipyrine clearance has been observed in patients with cirrhosis. Decreased antipyrine metabolism, while not apparent during the early stage of cirrhosis, appears to be specific for some stages of the disease 43 . Antipyrine plasma clearance and half-life have been determined in patients with acute viral hepatitis 44 . A prolonged plasma half-life and decreased plasma clearance of the drug was found at the time of acute illness and these returned to normal values during recovery. Antipyrine elimination has also been studied in patients with obstructive jaundice to predict disease outcome 45 . Half-life measured from 46 patients in this study was valuable in predicting disease outcome.
Plasma and saliva concentrations of antipyrine have been measured after an oral dose of 10 mg/kg antipyrine in patients 46 . Blood or saliva sampling began two to three hours after drug dosing and ended 24 to 48 hours later; six samples were collected for drug assay. Generally, three techniques were used in the analysis of antipyrine including spectrophotometry, gas chromatography and high performance liquid chromatography 43 . Antipyrine clearance was calculated as:
CL=0.693/t 1/2 . V d 42 or CL=Dose/AUC 47 .
One study used the antipyrine test to determine the oxidative drug-metabolizing capacity of the liver before and one to two months after liver transplantation 47 . A significant increase in antipyrine clearance was noted after liver transplantation compared with before transplantation. No significant differences in either clearance or half-life were noted between patients after liver transplantation and healthy control subjects. The advantage of the antipyrine test is its reliability, but environmental and genetic factors and concomitantly administered drugs may influence the test results and complicate interpretation of the results. The procedure is also time-consuming and cumbersome which limits its routine clinical use.
Aminopyrine Breath Test (ABT)
The determination of 14 CO 2 activity in a single breath collection, two hours after the oral administration of 14 C-labelled aminopyrine, was first developed as a quantitative assessment of hepatic function in humans in 1975 48 . Aminopyrine is rapidly and completely absorbed and distributed evenly throughout the body. It is negligibly protein-bound and is poorly extracted by the liver. Aminopyrine is metabolized primarily by the liver through demethylation by mixed-function oxidase enzyme systems. Therefore its clearance is predominantly associated with hepatic metabolizing capacity and unaffected by changes in hepatic blood flow 49 . The 14 CO 2 output is highly correlated with aminopyrine metabolic clearance 50 . The measurement of 14 CO 2 has been used as an index of hepatic microsomal activity in different circumstances including diagnosis of rejection after liver transplantation 51 , evaluation of hepatocellular dysfunction in hepatic disease 52 , and assessment of the severity of liver cirrhosis 53 . These studies indicate that ABT is a reliable indicator of the presence of cirrhosis particularly in alcoholic patients 52 . In addition, ABT correlated well with the severity of hepatic dysfunction 53 . It was also found that 14 CO 2 output decreased significantly in hepatocellular dysfunction but not in patients with cholestasis alone 52, 54 . This suggests that ABT is not clinically useful in identifying the presence of cirrhosis in patients with cholestatic liver disease.
When used as a predictive test of rejection after liver transplantation, ABT is a sensitive but not a specific parameter because sepsis and viral infection may also lead to a reduction of ABT. Biopsy is needed for differential diagnosis 51 . In another study, the aminopyrine breath test was used to predict the outcome of hepatic transplantation in pigs one and seven days following experimental liver transplantation. There were significant differences between the ABT results from the survivor group and the group that died within five days postoperatively 55 . Determination of 14 CO 2 activity (as a percentage of dose) in a single breath collection two hours after an oral dose of 14 Caminopyrine (2 µCi) to the patient is achieved by employing a liquid scintillation counter to quantify radioactivity. However, due to variable rates of oral absorption of 14 C-aminopyrine, a delay in elimination occurred in some patients which affected the inter-pretation of the results. A modified ABT following intravenous administration of 14 C-aminopyrine shortened the appearance time of the 14 CO 2 in the breath and enabled a more rapid turn-around of the results 52 . This method is feasible in patients maintained on artificial ventilation.
An advantage of the aminopyrine breath test is that it is technically easy to use and is a sensitive liver function test partly because it measures an hepatic metabolite, 14 CO 2 , rather than the disappearance of the parent compound. The disadvantage of ABT is that the administration of 14 C-aminopyrine is potentially hazardous even though the dose of radiation is comparable to a routine diagnostic chest X-ray, which limits its use in pregnant women and children 48 . A variable rate of gastric absorption of aminopyrine among individuals may influence the output of 14 CO 2 and this complicates the results when aminopyrine is taken orally. Endogenous CO 2 output may be altered in response to the patient's physical state which may also interfere with the results. In addition, aminopyrine is known to induce agranulocytosis in patients previously sensitized by pyrazolone derivatives 52 .
Erythromycin Breath Test (EBT)
Erythromycin breath test measures the production of 14 CO 2 over one hour after administration of 14 Cerythromycin. This test is based on the fact that the N-demethylation of erythromycin is catalyzed exclusively by P450 3A enzymes and the carbon atom that is removed as part of the methyl group should largely appear in the breath as carbon dioxide. By giving the patients an intravenous injection of a trace amount of 14 C N-methyl erythromycin, the rate of its subsequent demethylation in vivo, which represents the activity of P450 3A in humans, is estimated from the rate at which the patient produces 14 CO 2 in the breath 56 . This test involves intravenous injection of 3 µCi of 14 C-N-methyl erythromycin dissolved in 2.5 ml of 5% dextrose in water. At timed intervals during the next hour, the patient is asked to exhale through a tube, creating bubbles in a solution of 4 ml hyamine hydroxide that contains a trace amount of indicator thymolphthalein. Patients are instructed to generate bubbles until the blue colour vanishes, at which point 2 mmol of CO 2 has been trapped. Twelve millilitres of a scintillation fluid (Aquasol ® ) is then added to each vial, and the specific activity (content) of carbon-14 is determined by scintillation counting. The percentage of administered carbon-14 exhaled per minute is calculated at each time-point on the basis of an endogenous carbon dioxide production rate of 5 mmol CO 2 /m 2 of body surface area and is plotted as a function of time after injection. The resulting area under the curve estimates the percentage of injected carbon-14 exhaled in breath during the first hour after injection. This test was reported to be reproducible and reliable when it was performed in healthy male volunteers 57 . Clinically the erythromycin breath test has been used for predicting cyclosporine dosing requirements and blood levels in both kidney and liver transplantation patients respectively because cyclosporine is largely metabolized by CYP450 3A enzyme whose catalytic activity varies significantly among patients. This marked variation of catalytic activity in the P450 3A accounts for the ten-fold variation in the oral dose of cyclosporine required to achieve a target trough blood level. As the rate of 14 CO 2 exhaled in breath correlated significantly with the clearance of cyclosporine, the erythromycin breath test has been recommended as a useful guide in cyclosporine administration in patients who received organ transplantation 58, 59 . This was supported by the result from another study in a group of patients with psoriasis who received cyclosporine 60 . It was found that there was a strong inverse correlation between the production of CO 2 from N-demethylation of erythromycin and the mean blood levels of cyclosporine. Based on the observed relationship between the erythromycin breath test and the blood cyclosporine level at a given daily dose of cyclosporine, a mathematical model capable of predicting the cyclosporine blood level for each individual was developed:
Log (cyclosporine blood level, ng/ml)=1.7+0.099 (dose, mg/kg/day)-0.157 (breath test, % 14 C)+ 0.0055 (age).
This equation had a high predictive accuracy (R 2~0 .75) for psoriasis patients receiving cyclosporine. However, it may not be useful in other patient populations because patients in this study were receiving a relatively narrow range of daily doses of cyclosporine. In addition, patients in this study were generally healthy and psoriasis has no known effects on hepatic, intestinal or renal handling of drugs. In contrast, the majority of patients who receive cyclosporine are organ transplant recipients who often have varying degree of multi-organ dysfunction. Therefore, more extensive investigations into the use of the erythromycin breath test, as a predictor of blood cyclosporine levels in differing clinical situations are required. So far, the erythromycin breath test has been widely accepted as a measure of the in vivo CYP 3A activity in human liver 61, 62 . Its use is avoided if exposure to a radioactive compound is contraindicated. Intravenous administration of 14 C erythromycin is needed to exclude the CYP 3A metabolism at the intestinal mucosal site which is another significant source of CYP 3A.
Nondepolarizing Neuromuscular Blocking Agents
Early assessment of graft liver function during liver transplantation in humans by measuring neuromuscular blockade induced by vecuronium or rocuronium has been studied recently 63, 64 , demonstrating a significant correlation between the recovery time from neuromuscular blockade and graft liver function during the early postoperative period. A statistically significant prolongation of recovery times for both drugs was observed in patients with primary dysfunction after transplantation. This suggests that assessment of recovery of normal neuromuscular function by monitoring the train-of-four muscle twitch response may be a simple online method for predicting graft liver function during liver transplantation, provided a nondepolarizing neuromuscular blocking agent which is metabolized and eliminated mainly via the liver is used. Vecuronium and rocuronium are both eliminated mainly by the hepatic route. More than 50% of a vecuronium dose is found in liver tissue five minutes after injection and more than 40% was calculated to be excreted in the bile within 24 hours 65 . Of the vecuronium excreted in bile, 50% was present as the 3-hydroxy metabolite in animals 66 . Hepatic elimination of rocuronium is reported to account for 80% of the injected dose 67 . Little if any metabolism of rocuronium apparently takes place and no metabolites were detected in liver, plasma, or urine. Further studies are needed to determine the predictive value of vecuronium, rocuronium or other nondepolarizing neuromuscular blocking agents' duration of action for liver function assessment during liver transplantation.
OTHER DRUGS
Other drugs have been used as research tools or in clinical practice for quantifying liver function. These tests are not as well developed as those already reviewed and there is limited information on them. None of these has been used in assessment of graft liver function in liver transplant patients. The use of trimethadione, methacetin and allopurinol is discussed.
Trimethadione tolerance test
This test measures the serum dimethadione/ trimethadione ratio four hours after an oral dose of 4 mg/kg of trimethadione 68 . The ratio of dimethadione to trimethadione serves as a marker of hepatic metabolic capacity because trimethadione is completely absorbed from the gastrointestinal tract via first order kinetics. In addition, it is not bound to plasma proteins, is exclusively metabolized by a cytochrome P450-dependent monooxygenase enzyme in the liver to dimethadione which is the only metabolite 69 . It has been demonstrated to be a promising test drug for assessment of liver function in more than 1000 patients with liver disease in Japan 70, 71 . The results have shown that trimethadione metabolism is reduced as liver disease progresses (as judged both pathologically and histologically). This test has also been used to estimate the severity of liver damage in patients with cirrhosis 72 and to assess the functional reserve of the liver in patients with hepatocellular carcinoma 68 . These studies showed good correlation between dimethadione/trimethadione ratio and the severity of liver damage. It was found that a dimethadione/trimethadione ratio lower than 0.4 was associated with pronounced histological changes, whereas a higher ratio (>0.4) was associated with mild histological changes. Good correlations were found between the dimethadione/trimethadione ratio and primary biochemical parameters 72 . The ratio has currently been used in liver surgery to evaluate liver reserve capacity before and after operation. The critical ratio for survival is approximately 0.15 68 . So far this test has not been used in determining graft liver function in liver transplant patients. However, the advantage of estimating the hepatic drug-metabolizing capacity by a single blood sample taken four hours after an oral dose of the drug without the need for calculating any pharmacokinetic parameter makes it likely that this test will be suitable for liver transplant patients. It should only be used for short periods: long-term use may cause bone marrow suppression.
C-methacetin breath test
13 C-methacetin is metabolized in the liver by O-demethylation to 13 CO 2 and paracetamol (acetaminophen). The rate of O-demethylation of methacetin may be assessed by measuring the 13 CO 2 in the exhaled air 20 min after an oral dose of 13 C-methacetin. The test has been used to evaluate liver damage in patients with chronic liver disease 73 . While 13 C is a stable isotope when compared with 14 C, this test is still unsuitable for pregnant women and children.
N-methacetin urine test
This test was developed to estimate P450 enzyme activity in paediatric patients 74 . Elimination rates of the stable isotope 15 N are measured in urine after an oral dose of the 15 N-labeled methacetin. This is a more complex test involving a two step analysis for total nitrogen (N 2 ) content and 15 N 2 content in the urine. A nine-hour urine collection is required for estimating the per cent of the administered dose that is eliminated, making it a time-consuming procedure not suitable for routine clinical use 75 .
Allopurinol
Allopurinol is a well-known drug used in the treatment of gout. It is metabolized by xanthine oxidase (dehydrogenase) to oxypurinol 76 . Xanthine oxidase is located primarily in the liver and intestinal mucosa. Allopurinol and oxypurinol are both easily assayed in plasma. Thus, a test was developed to determine liver function by measuring plasma allopurinol disappearance (and oxypurinol appearance) after an intravenous dose of allopurinol 76 . Plasma concentrations of allopurinol and oxypurinol were followed for an hour after drug dosing by employing a reversed-phase HPLC technique. The data were processed using a computer-based pharmacokinetic model which enabled calculation of pharmacokinetic parameters which reflect liver function. While this method satisfies most of the requirements for characterizing liver function using drug metabolism, it lacks specificity for the liver since xanthine oxidase not only exists in liver but in other tissues as well 69 . Allopurinol causes granulomatous hepatitis in hypersensitive individuals 77 . The procedure is also somewhat cumbersome to be used routinely.
CONCLUSIONS
The liver plays an important role in energy metabolism and synthesis of plasma proteins and clotting factors. In addition, it is the site where many substances both endogenous, (such as steroids and hormones) and exogenous (such as drugs), undergo biochemical transformation and alteration of their biological activities. Due to this multiplicity of roles, early detection of graft failure is vital to the liver transplant patient's survival. Assessment of the disposition of agents which are mainly eliminated via the hepatic route may be used to assess the liver's functional capacity. Drugs which have been used for this purpose include lignocaine, indocyanine green, caffeine, galactose, antipyrine, aminopyrine, erythromycin, nondepolarizing neuromuscular blocking agents, trimethadione, methacetin and allopurinol.
None of these drugs is ideal as a probe for liver function. Measurement of mono-ethyleneglycinexylidide (MEGX) formation from lignocaine is useful and has been used widely in liver transplantation to assess liver graft function; but results can be affected by the use of drugs that may alter liver perfusion and interfere with the CYP450 enzyme system. The indocyanine green clearance test may be used but both blood flow and hepatocellular function affect the test results. Tests of caffeine clearance, galactose elimination capacity and antipyrine clearance all require serial blood sampling which are time-consuming, technically cumbersome and expensive. In addition, various host factors such as smoking, genetic and environmental changes may affect the proper interpretation of these tests. The aminopyrine breath test is non-invasive, but results are affected by gastric empting and the patient's physical status. The potential hazard of exposure to radioactive compounds limits the widespread use of both aminopyrine and erythromycin breath tests clinically.
Monitoring of the recovery rate of neuromuscular blockade induced by vecuronium or rocuronium, which are predominantly cleared by the liver, may provide valuable prediction of liver graft function during transplantation. Monitoring of neuromuscular function during surgery is a routine procedure, thus this test adds no extra clinical burden and has the potential to be easily accepted. There is limited data available in this area. Further studies are needed before neuromuscular blockade may be routinely used to assess liver function after transplantation.
